Estradiol/norethisterone transdermal - Solvay

Drug Profile

Estradiol/norethisterone transdermal - Solvay

Alternative Names: Bio-E/P-Gel; E2/NETA gel - Solvay; Estradiol/NETA - Solvay; Estradiol/norethisterone gel - Solvay; Estradiol/progestogen gel - Solvay

Latest Information Update: 23 Mar 2007

Price : $50

At a glance

  • Originator Antares Pharma; BioSante Pharmaceuticals
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Menopausal syndrome

Most Recent Events

  • 23 Mar 2007 Discontinued - Phase-I for Menopausal syndrome in World (Transdermal)
  • 23 Mar 2007 Discontinued - Phase-II/III for Menopausal syndrome in USA (Transdermal)
  • 30 Jun 2004 Phase-II/III clinical trials in Menopausal syndrome in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top